Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 9
2010 19
2011 32
2012 80
2013 158
2014 226
2015 233
2016 302
2017 338
2018 347
2019 405
2020 444
2021 481
2022 413
2023 384
2024 136

Text availability

Article attribute

Article type

Publication date

Search Results

3,456 results

Results by year

Filters applied: . Clear all
Page 1
MDV3100 for the treatment of prostate cancer.
Mukherji D, Pezaro CJ, De-Bono JS. Mukherji D, et al. Expert Opin Investig Drugs. 2012 Feb;21(2):227-33. doi: 10.1517/13543784.2012.651125. Epub 2012 Jan 10. Expert Opin Investig Drugs. 2012. PMID: 22229405 Review.
INTRODUCTION: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. ...AREAS COVERED: This review will cov …
INTRODUCTION: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men …
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. Armstrong AJ, et al. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. J Clin Oncol. 2019. PMID: 31329516 Free PMC article. Clinical Trial.
PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We evaluated the efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate can …
PURPOSE: Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated significant benefits in metastatic and nonmetastatic ca …
Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate cancer.
Li J, Wu H, Lv S, Quan D, Yang D, Xu J, Chen B, Ou B, Wu S, Wei Q. Li J, et al. Pharmazie. 2022 Feb 1;77(2):59-66. doi: 10.1691/ph.2022.1948. Pharmazie. 2022. PMID: 35209965
Background: Patients with prostate cancer often develop resistance to androgen deprivation therapy, a condition called castration-resistant prostate cancer (CRPC). Enzalutamide (MDV3100) can prolong the survival of patients with CRPC after chemotherapy, but 50% of p …
Background: Patients with prostate cancer often develop resistance to androgen deprivation therapy, a condition called castration-resistant …
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.
BACKGROUND: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. ...Rates of fatigue, diarrhea, and hot flashes were higher in the enzalutamide group. Seizures we …
BACKGROUND: Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the majo …
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Tran C, et al. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9. Science. 2009. PMID: 19359544 Free PMC article. Clinical Trial.
Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the efficiency of its nuclear translocation, and impair both DNA binding to androgen response elements and recruitment of coactivators. RD162 and …
Both compounds bind to the androgen receptor with greater relative affinity than the clinically used antiandrogen bicalutamide, reduce the e …
The evolution of antiandrogens: MDV3100 comes of age.
Dumas L, Payne H, Chowdhury S. Dumas L, et al. Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3. doi: 10.1586/era.11.210. Expert Rev Anticancer Ther. 2012. PMID: 22316360 No abstract available.
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G. Lowentritt B, et al. Urol Oncol. 2023 May;41(5):253.e1-253.e9. doi: 10.1016/j.urolonc.2023.03.003. Epub 2023 Apr 13. Urol Oncol. 2023. PMID: 37061452 Free article.
The median time to achieving PSA90 was 3.1 months with apalutamide and 5.2 months with enzalutamide. CONCLUSIONS: This real-world study demonstrated that apalutamide initiation is associated with a significantly higher likelihood of achieving 90% reduction in PSA as compar …
The median time to achieving PSA90 was 3.1 months with apalutamide and 5.2 months with enzalutamide. CONCLUSIONS: This real-world stu …
Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao B, Kim M, Reizine NM, Moreira DM. Cao B, et al. Eur Urol Oncol. 2023 Jun;6(3):237-250. doi: 10.1016/j.euo.2023.01.001. Epub 2023 Jan 20. Eur Urol Oncol. 2023. PMID: 36682938 Review.
Enzalutamide was also ranked as the most toxic regarding headache across all prostate cancer entities (SUCRA 0%, for mCRPC, 1% for nmCRPC, and 3% for mCSPC). ...Side effects were similar, apart from higher risk of high blood pressure and headache risk with enzalutamide …
Enzalutamide was also ranked as the most toxic regarding headache across all prostate cancer entities (SUCRA 0%, for mCRPC, 1% for nm …
KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, Hu J, Wang X, Wang X, Su P, Chen S, Qu S, Shi B, Xiong X, Chen W, Dong X, Han B. Gao L, et al. Cancer Res. 2021 Feb 15;81(4):1026-1039. doi: 10.1158/0008-5472.CAN-20-1965. Epub 2020 Dec 4. Cancer Res. 2021. PMID: 33277366
The new generation androgen receptor (AR) pathway inhibitor enzalutamide can prolong the survival of patients with metastatic prostate cancer. ...In turn, the transcriptionally active AR stimulated KIF15 expression. KIF15 inhibitors alone or in combination with enzaluta …
The new generation androgen receptor (AR) pathway inhibitor enzalutamide can prolong the survival of patients with metastatic prostat …
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
In a clinically valid murine xenograft model of human CRPC, ARN-509 showed greater efficacy than MDV3100. Maximal therapeutic response in this model was achieved at 30 mg/kg/d of ARN-509, whereas the same response required 100 mg/kg/d of MDV3100 and higher steady-st …
In a clinically valid murine xenograft model of human CRPC, ARN-509 showed greater efficacy than MDV3100. Maximal therapeutic respons …
3,456 results